Boston Scientific owns more than 30% of the emphysema treatment device developer, which is targeting $86.3m in its offering.
US-based emphysema treatment system developer Pulmonx, which counts medical device maker Boston Scientific and steelmaker Posco as investors, filed on Friday to raise up to $86.3m in an initial public offering.
Pulmonx is working on a minimally invasive system that will treat patients suffering from severe emphysema, a form of chronic obstructive pulmonary disease affecting the lungs, by combining lung and pulmonary analysis technology with an endobronchial valve.
The IPO proceeds will fund an expansion in sales and marketing…
